Immune-Endocrine Crosstalk in Metabolic Aging: Mechanisms, Clinical Implications, and Emerging Therapeutic Directions

Abstract

Metabolic aging is characterized by progressive dysregulation of glucose and lipid metabolism, often leading to comorbidities such as type 2 diabetes, cardiovascular disease, and frailty. Recent evidence highlights a complex interplay between immune and endocrine systems in driving these age-related metabolic changes. This review synthesizes current PubMed literature on immune-endocrine crosstalk in metabolic aging, emphasizing mechanistic insights, clinical features, diagnostic strategies, and emerging therapies. The integration of immunosenescence with hormonal alterations underpins disease risk, while targeting these pathways offers evolving therapeutic promise for clinicians managing aging populations.

Introduction

Metabolic aging refers to the gradual decline in metabolic efficiency and homeostasis associated with advancing age. This process is influenced by intersecting biological systems, with mounting data suggesting that immune and endocrine networks exert reciprocal regulatory effects on metabolism. Understanding this crosstalk is essential for identifying at-risk individuals, optimizing clinical management, and developing novel interventions. In this review, we consolidate mechanistic, epidemiological, and clinical perspectives on immune-endocrine interactions in metabolic aging, focusing on their implications for contemporary medical practice.

Epidemiology / Disease Burden

The global demographic shift towards older populations has amplified the burden of metabolic diseases. Epidemiological studies report that over 35% of adults above 65 years exhibit features of metabolic syndrome, with higher prevalence rates of insulin resistance, dyslipidemia, and sarcopenic obesity. These disorders contribute significantly to morbidity, healthcare utilization, and mortality in the elderly. Regional studies, such as those from the National Health and Nutrition Examination Survey (NHANES), underscore the rising incidence of metabolic comorbidities, highlighting the urgency for improved risk stratification and preventive strategies that account for age-associated immune and endocrine alterations.

Pathophysiology

Metabolic aging is orchestrated by intricate molecular pathways involving both immune and endocrine systems. Immunosenescence, characterized by a shift towards pro-inflammatory cytokine profiles ("inflammaging"), disrupts insulin signaling and adipose tissue function. Concurrently, endocrine changes—such as reduced growth hormone, altered sex steroid levels, and impaired hypothalamic-pituitary-adrenal (HPA) axis regulation—exacerbate metabolic imbalance. Adipose tissue macrophages adopt an activated phenotype, secreting TNF-α and IL-6, which impair adipocyte insulin sensitivity. Dysregulated glucocorticoid and thyroid hormone signaling further modulate immune cell differentiation and metabolic gene expression. The reciprocal reinforcement of chronic inflammation and hormonal dysregulation accelerates tissue degeneration and metabolic decline.

Risk Factors

Several modifiable and non-modifiable risk factors potentiate immune-endocrine crosstalk in metabolic aging. Advanced age, genetic predisposition, and female sex (due to menopause-associated estrogen decline) are prominent non-modifiable risks. Lifestyle factors—including physical inactivity, high-fat diets, chronic psychosocial stress, and exposure to environmental toxins—exacerbate immune activation and endocrine dysfunction. Chronic infections (e.g., CMV, HIV) and comorbid autoimmune disorders further intensify immune dysregulation. Obesity and central adiposity amplify adipose tissue inflammation and hormonal resistance, synergistically increasing susceptibility to metabolic syndrome and related complications.

Clinical Features

Patients experiencing immune-endocrine dysregulation in metabolic aging often present with a constellation of clinical manifestations. These include central obesity, impaired glucose tolerance, hypertension, dyslipidemia, and reduced muscle mass (sarcopenia). Subtle features such as fatigue, cognitive decline, and increased susceptibility to infections may reflect underlying immunosenescence and hormonal insufficiency. Notably, elderly individuals frequently exhibit blunted febrile responses and atypical presentations of metabolic decompensation, necessitating a high index of clinical suspicion and comprehensive assessment protocols.

Diagnosis

Diagnostic evaluation of metabolic aging with immune-endocrine involvement requires a multidimensional approach. Standard metabolic assessments include fasting glucose, HbA1c, lipid profiles, and anthropometric measurements. Immunological markers—such as circulating inflammatory cytokines (IL-6, CRP), leukocyte phenotyping, and assessment of T-cell senescence—provide additional insights into the inflammatory milieu. Endocrine evaluation encompasses serum cortisol, DHEA-S, thyroid function tests, and sex hormone quantification. Novel biomarkers, including adipokines (adiponectin, leptin) and markers of mitochondrial dysfunction, are increasingly integrated into research protocols to refine risk prediction and monitor therapeutic response.

Treatment & Management

Management strategies for metabolic aging with immune-endocrine crosstalk are multifaceted. Lifestyle interventions remain foundational, emphasizing individualized exercise programs, dietary optimization (Mediterranean or DASH diets), and weight reduction. Pharmacological therapies may target glycemic control (metformin, SGLT2 inhibitors), dyslipidemia (statins, PCSK9 inhibitors), and hypertension (ACE inhibitors, ARBs). In select cases, hormone replacement therapy (HRT) or DHEA supplementation is considered, particularly in symptomatic hypogonadism or adrenal insufficiency. Immunomodulatory agents, such as low-dose methotrexate or IL-1/IL-6 antagonists, are being explored for their potential to ameliorate chronic inflammation and metabolic derangements.

Recent Advances / Emerging Therapies

Emerging therapies targeting immune-endocrine pathways are reshaping the landscape of metabolic aging management. Senolytic agents, designed to eliminate senescent immune cells, have shown promise in preclinical studies for reducing systemic inflammation and improving insulin sensitivity. Novel modulators of the gut microbiome, including prebiotics and postbiotics, are under investigation for their capacity to recalibrate immune-metabolic homeostasis. Advances in precision medicine—such as genetic risk profiling and personalized hormone replacement protocols—offer prospects for individualized therapy. Trials evaluating JAK-STAT inhibitors, GLP-1 receptor agonists, and selective androgen receptor modulators (SARMs) are ongoing, with early data suggesting benefits in metabolic control and functional outcomes.

Guideline Recommendations

Contemporary guidelines from entities such as the American Diabetes Association, Endocrine Society, and European Society of Cardiology stress comprehensive metabolic assessment in older adults, with consideration of immune and endocrine statuses. Recommendations include routine screening for metabolic syndrome, proactive management of comorbidities, and cautious use of hormone therapies—balancing efficacy with potential risks. Multidisciplinary care, incorporating endocrinologists, geriatricians, and immunologists, is advocated for optimizing patient outcomes. Ongoing guideline updates are expected as new evidence on immune-endocrine crosstalk emerges.

Conclusion

Immune-endocrine crosstalk plays a pivotal role in the pathogenesis and progression of metabolic aging. Integrating mechanistic insights with clinical practice is essential for early identification, risk stratification, and management of affected individuals. Advances in understanding the bidirectional interactions between immunosenescence and hormonal dysregulation are driving the development of targeted therapeutics, with the potential to enhance longevity and quality of life in aging populations. Continued research, interdisciplinary collaboration, and adherence to evolving clinical guidelines will be critical in addressing the growing burden of metabolic disorders in the elderly.